We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

96 hedge funds and large institutions have $586M invested in Aclaris Therapeutics in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

116% more call options, than puts

Call options by funds: $1.46M | Put options by funds: $675K

38% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 29

9% more capital invested

Capital invested by funds: $536M → $586M (+$50.4M)

1.35% more ownership

Funds ownership: 98.94% → 100.29% (+1.4%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less funds holding

Funds holding: 100 → 96 (-4)

20% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 15

Holders
96
Holders Change
-4
Holders Change %
-4%
% of All Funds
2.2%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
12
Increased
40
Reduced
29
Closed
15
Calls
$1.46M
Puts
$675K
Net Calls
+$782K
Net Calls Change
+$1.04M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$14.7M
2
Franklin Resources
Franklin Resources
California
+$7.3M
3
RSCM
Rock Springs Capital Management
Maryland
+$6.02M
4
BlackRock
BlackRock
New York
+$3.77M
5
RHJA
Rice Hall James & Associates
California
+$3.47M

Top Sellers

1
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
-$9.24M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.51M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$5.28M
4
HCM
Highbridge Capital Management
New York
-$5.26M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$4.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
51
Credit Suisse
Switzerland
$802K +$140K +7,563 +23%
TI
52
Telemetry Investments
New York
$719K -$370K -20,000 -36%
CCM
53
Cadence Capital Management
Massachusetts
$665K +$66.4K +3,593 +12%
New York State Common Retirement Fund
54
New York State Common Retirement Fund
New York
$592K +$109K +5,900 +25%
PI
55
Putnam Investments
Massachusetts
$582K -$498K -26,947 -48%
ARTA
56
A.R.T. Advisors
New York
$578K -$523K -28,329 -49%
AllianceBernstein
57
AllianceBernstein
Tennessee
$575K +$96.1K +5,200 +22%
RhumbLine Advisers
58
RhumbLine Advisers
Massachusetts
$542K +$91.3K +4,943 +22%
Fidelity International
59
Fidelity International
Bermuda
$504K – – –
Susquehanna International Group
60
Susquehanna International Group
Pennsylvania
$460K +$191K +10,334 +81%
Manulife (Manufacturers Life Insurance)
61
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$420K +$53K +2,866 +16%
CC
62
Caxton Corporation
New Jersey
$390K -$30.1K -1,628 -8%
AIG
63
American International Group
New York
$348K +$47.2K +2,554 +17%
ProShare Advisors
64
ProShare Advisors
Maryland
$330K -$13.3K -718 -4%
Dimensional Fund Advisors
65
Dimensional Fund Advisors
Texas
$314K – – –
State of Wisconsin Investment Board
66
State of Wisconsin Investment Board
Wisconsin
$300K – – –
FPC
67
Falcon Point Capital
California
$300K +$278K +15,044 New
Wells Fargo
68
Wells Fargo
California
$297K -$8K -433 -3%
Squarepoint
69
Squarepoint
New York
$287K -$456K -24,683 -63%
MIM
70
MetLife Investment Management
New Jersey
$263K +$59.9K +3,244 +33%
DekaBank Deutsche Girozentrale
71
DekaBank Deutsche Girozentrale
Germany
$243K – – –
Los Angeles Capital Management
72
Los Angeles Capital Management
California
$226K +$210K +11,340 New
VOYA Investment Management
73
VOYA Investment Management
Georgia
$226K +$210K +11,341 New
MLICM
74
Metropolitan Life Insurance Company (MetLife)
New York
$221K +$66.3K +3,589 +48%
State Board of Administration of Florida Retirement System
75
State Board of Administration of Florida Retirement System
Florida
$215K +$199K +10,787 New
1 2
3
4 5

ACRS Hedge Fund Activity: Q2 2018 in Review

96 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2018, worth a combined $586M — up 9.4% from $536M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of ACRS and 12 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 40 added.

The largest buyer was Fidelity Investments, adding an estimated $14.7M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $9.24M sold.

  • 96 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2018, down from 100 in Q1 2018.
  • Funds reported $586M of Aclaris Therapeutics stock for Q2 2018, up 9.4% quarter-over-quarter.
  • 12 funds opened new Aclaris Therapeutics positions in Q2 2018 and 15 closed out, a net change of -3 holders.
  • The largest Aclaris Therapeutics buyer in Q2 2018 was Fidelity Investments, an estimated $14.7M added.
  • The largest Aclaris Therapeutics seller in Q2 2018 was Loomis, Sayles & Company, an estimated $9.24M sold.

Based on aggregated 13F filings for Q2 2018.